{"id":23925,"date":"2023-12-01T09:25:48","date_gmt":"2023-12-01T08:25:48","guid":{"rendered":"https:\/\/porib.com\/?p=23925"},"modified":"2023-12-01T09:25:48","modified_gmt":"2023-12-01T08:25:48","slug":"eficiencia-de-lorlatinib-en-pacientes-con-cancer-de-pulmon-no-microcitico-avanzado-alk","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/eficiencia-de-lorlatinib-en-pacientes-con-cancer-de-pulmon-no-microcitico-avanzado-alk\/","title":{"rendered":"Eficiencia de Lorlatinib en pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico avanzado ALK+"},"content":{"rendered":"<div class=\"col80p\">\n<p>Lorlatinib es un tratamiento dominante frente a alectinib y coste-efectivo frente brigatinib, de acuerdo a los resultados recogidos en el art\u00edculo <strong>\u201cCost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain\u201d<\/strong>, en el que ha trabajado PORIB.<br \/>\nLos resultados del estudio han sido publicados en la revista<em> ClinicoEconomics and Outcomes Research<\/em>, y ten\u00edan como objetivo estimar la eficiencia de lorlatinib en el tratamiento en primera l\u00ednea de pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) avanzado ALK+.<\/p>\n<p><a href=\"https:\/\/porib.com\/wp-content\/uploads\/2023\/12\/203.pdf\" target=\"_blank\" rel=\"noopener\">M\u00c1S INFORMACI\u00d3N<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lorlatinib es un tratamiento dominante frente a alectinib y coste-efectivo frente brigatinib, de acuerdo a los resultados recogidos en el art\u00edculo \u201cCost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain\u201d, en el que ha trabajado PORIB. Los resultados del estudio han sido publicados&#8230; <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/porib.com\/en\/eficiencia-de-lorlatinib-en-pacientes-con-cancer-de-pulmon-no-microcitico-avanzado-alk\/\" class=\"excerpt-read-more\">Read More<i class=\"fa fa-caret-right icon-caret-right\"><\/i><\/a><\/p>\n","protected":false},"author":4,"featured_media":23927,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[67],"tags":[],"class_list":["post-23925","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ultimas-noticias"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/23925"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=23925"}],"version-history":[{"count":1,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/23925\/revisions"}],"predecessor-version":[{"id":23928,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/23925\/revisions\/23928"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media\/23927"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=23925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=23925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=23925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}